MX2022015857A - Compuestos de dihidroquinolin sulfonamida de heteroalquilo. - Google Patents
Compuestos de dihidroquinolin sulfonamida de heteroalquilo.Info
- Publication number
- MX2022015857A MX2022015857A MX2022015857A MX2022015857A MX2022015857A MX 2022015857 A MX2022015857 A MX 2022015857A MX 2022015857 A MX2022015857 A MX 2022015857A MX 2022015857 A MX2022015857 A MX 2022015857A MX 2022015857 A MX2022015857 A MX 2022015857A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydroquinoline
- heteroalkyl
- sulfonamide compounds
- compounds
- present
- Prior art date
Links
- -1 Heteroalkyl dihydroquinoline sulfonamide compounds Chemical class 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de dihidroquinolinsulfonamida de heteroalquilo de Fórmula I, (ver Fórmula) I; y sales farmacéuticamente aceptables de los mismos, que son inhibidores de los canales de sodio activados por voltaje, en particular Nav1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio tales como trastornos del dolor, tos y picazón. También se proporcionan composiciones farmacéuticas que contienen compuestos de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037000P | 2020-06-10 | 2020-06-10 | |
| PCT/US2021/036898 WO2021252822A1 (en) | 2020-06-10 | 2021-06-11 | Heteroalkyl dihydroquinoline sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015857A true MX2022015857A (es) | 2023-01-24 |
Family
ID=76845313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015857A MX2022015857A (es) | 2020-06-10 | 2021-06-11 | Compuestos de dihidroquinolin sulfonamida de heteroalquilo. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230227442A1 (es) |
| EP (1) | EP4165032A1 (es) |
| JP (1) | JP2024514990A (es) |
| AU (1) | AU2021288190A1 (es) |
| CA (1) | CA3183948A1 (es) |
| MX (1) | MX2022015857A (es) |
| WO (1) | WO2021252822A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4347584A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| EP4346818A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| WO2022256702A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| EP4347033A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| WO2022256622A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| EP4347583A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| EP3390392B1 (en) | 2015-12-18 | 2021-10-06 | Amgen Inc. | Alkyl dihydroquinoline sulfonamide compounds |
-
2021
- 2021-06-11 JP JP2022575972A patent/JP2024514990A/ja active Pending
- 2021-06-11 CA CA3183948A patent/CA3183948A1/en active Pending
- 2021-06-11 WO PCT/US2021/036898 patent/WO2021252822A1/en unknown
- 2021-06-11 MX MX2022015857A patent/MX2022015857A/es unknown
- 2021-06-11 EP EP21739832.0A patent/EP4165032A1/en active Pending
- 2021-06-11 AU AU2021288190A patent/AU2021288190A1/en active Pending
- 2021-06-11 US US18/009,689 patent/US20230227442A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4165032A1 (en) | 2023-04-19 |
| JP2024514990A (ja) | 2024-04-04 |
| WO2021252822A1 (en) | 2021-12-16 |
| US20230227442A1 (en) | 2023-07-20 |
| CA3183948A1 (en) | 2021-12-16 |
| AU2021288190A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015857A (es) | Compuestos de dihidroquinolin sulfonamida de heteroalquilo. | |
| CR20220631A (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2022015622A (es) | Compuestos de dihidroquinolin sulfonamida de ciclopropilo. | |
| MX2022012780A (es) | Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados. | |
| MX2021005924A (es) | Compuestos y metodos de uso de los mismos para el tratamiento del cancer. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| MX2015017215A (es) | Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio. | |
| GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2023001997A (es) | Compuestos biciclicos, composiciones y usos de los mismos. | |
| PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| MX2022006736A (es) | Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas. | |
| MX2022006086A (es) | Derivados de piridopirimidinona como antagonistas de ahr. | |
| MX2022013401A (es) | Compuestos de azalactama como inhibidores de hpk1. | |
| MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| MX2023009285A (es) | Compuestos novedosos. | |
| MX2023006578A (es) | Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas. | |
| MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. |